Featured Company News - FDA Approves Abbott's MRI-Compatible Ellipse ICDs
Research Desk Line-up: Fonar Post Earnings Coverage
LONDON, UK / ACCESSWIRE / September 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Abbott Laboratories (NYSE: ABT) ("Abbott"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=ABT. The Company announced on September 22, 2017, that its magnetic resonance imaging (MRI) compatible implantable cardioverter defibrillator (ICD) device, Ellipse, is now approved by the Food and Drug Administration (FDA). The ICD is used for cardiac patients who need an MRI scan. The life-saving device for cardiac patients suffering from ventricular tachycardia or tachyarrhythmia is used with the pacemaker to treat abnormally fast heart rhythms. For immediate access to our complimentary reports, including today's coverage, register for free now at:
http://protraderdaily.com/register/
Discover more of our free reports coverage from other companies within the Medical Appliances & Equipment industry. Pro-TD has currently selected Fonar Corporation (NASDAQ: FONR) for due-diligence and potential coverage as the Company reported on September 14, 2017, its financial results for FY17 as of June 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Fonar when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ABT; also brushing on FONR. Go directly to your stock of interest and access today's free coverage at:
http://protraderdaily.com/optin/?symbol=ABT
http://protraderdaily.com/optin/?symbol=FONR
About Ventricular Tachycardia or Tachyarrhythmia
Ventricular tachycardia or tachyarrhythmia is a heart condition in which the electrical signals in the lower chamber of the heart gets fired erratically, leading to a rapid increase in the speed of heartbeats. As a result, the heart may become unable to pump blood normally as and when needed. This may cause conditions where the patients may suffer from light-headedness, chest pains, and shortness of breath. This malfunction of the heart may, over time, lead to potentially life-threatening conditions, such as arrhythmia, heart failure, stroke, or cardiac arrest.
About The ICD
The Implantable Cardioverter Defibrillator (ICD) is a device that uses electrical pulses or shocks to prevent arrhythmia, which may lead to a sudden cardiac arrest (SCA). In SCA, the heart suddenly stops beating, resulting in the unavailability of blood in the brain and other important organs, ultimately leading to death within minutes.
Ventricular tachycardia or tachyarrhythmia must be treated with electrical signals to repair the hyper-functioning of the heart immediately, and ICDs, which are usually small in shape and size, help to do this. The ICDs are pacemaker-compatible and implanted in the heart with the pacemaker devices.
About The Lead
A lead is a part of a pacemaker or ICD implantation procedure where a thin insulated wire is passed through the vein. The tip of the lead connects to the heart tissue, while the other end is attached to the ICD. It can carry electrical signals from the ICD to the heart and it also transmits all necessary information from the heart reversely to the device.
Abbott's widely used and highly acclaimed Ellipse ICD comes with the Tendril MRI pacing lead and Durata and Optisure high voltage leads that can send electrical signals to treat abnormal functions of the heart, apart from letting the body undergo MRI scans if needed.
About MR-conditional ICD
"MR-conditional" or "MRI ready" ICDs are designed to let the patients safely undergo an MRI scan. These ICDs have immediate access to imaging modalities that offer critical information and optimally-detailed images when making a patient-diagnosis for healthcare professionals.
About Abbott's TailoredTherapy™
Abbott's TailoredTherapy™ is an approach that makes the Abbott-engineered, optimized ICD therapy efficient in improving patient safety. The technologies that make the approach a game-changer include the following features:
DeFT Response™ Technology - Allows physicians to customize therapy delivered by the Ellipse ICD so as to ensure that each patient's unique need is taken care of. It also removes the need of an initial shock at the time of implantation.
SecureSense™ - Abbott's SecureSense algorithm provides proper sensing and monitoring of the heart even if there is an external interference (also known as "lead noise") so that no unnecessary therapy is initiated for the patient.
DynamicTx™ - Abbott's DynamicTx algorithm, ensures consistent evaluation of the lead and adapts the path of the electrical signal to offer the needed therapy.
Additionally, the data captured by the ICDs can be remotely sent to physicians via the Merlin.net™ Patient Care Network so that in case of any need of intervention, the physicians can intervene with necessary inputs.
A little bit of History
In February 2017, Abbott received FDA's approval for the Assurity MRI pacemaker, the world's smallest, longest-lasting wireless MRI-compatible pacemaker and the Tendril MRI pacing lead. The pacemaker was equipped with a similar technology as the Ellipse ICD that diminished the need for cardiac patients to visit clinics as the data required for evaluation of the conditions of the heart could be sent remotely.
The Assurity MRI pacemaker is paired with Abbott's MRI Activator handheld device to initiate previously programmed and customized MRI settings for individual patients. This effectively eliminates the effort, time, and inconvenience of setting the pacemaker that is generally required before and after an MRI scan.
Conclusion
The latest FDA-approval will allow Abbott to further grow its already strong portfolio of MRI compatible products. Abott continues to work with various regulatory agencies for approval of its MR-conditional labeling for pacemakers, ICDs, and cardiac resynchronization therapy (CRT) devices that benefit cardiac patients around the world.
Last Close Stock Review
At the closing bell, on Monday, September 25, 2017, Abbott Laboratories' stock rose slightly by 0.19%, ending the trading session at $52.61. A total volume of 9.64 million shares have exchanged hands, which was higher than the 3-month average volume of 5.17 million shares. The Company's stock price surged 7.56% in the last three months, 17.70% in the past six months, and 24.70% in the previous twelve months. Moreover, the stock soared 36.97% since the start of the year. The stock is trading at a PE ratio of 80.81 and has a dividend yield of 2.01%. The stock currently has a market cap of $91.57 billion.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@protraderdaily.com
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
